TheranosticTrials.org

Clinical Trial · NCT00978211

DOTA-TOC in Metastasized Neuroendocrine Tumors

Overview

The investigators aim to explore the efficacy of \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC therapy in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and long-term safety profile of systemic \[90Y-DOTA\]-TOC and \[177LuDOTA\]-TOC treatment in metastasized neuroendocrine cancer patients. Adverse events are assessed according to the criteria of the National Cancer Institute. Survival analyses are performed using multiple regression models.

Sponsor

University Hospital, Basel, Switzerland

Phase

Phase 2

Contacts

Martin A Walter, MD, Dr. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT00978211

Drug / Compound

TOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

TOC

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

Eligibility

Inclusion

  • stage IVc disease by definition of the American Joint Committee on Cancer, i.e. occurrence of distant metastases
  • visible tumor uptake in the pretherapeutic somatostatin receptor subtype 2 scintigraphy (111In-Octreoscan)
  • histologically confirmed neuroendocrine cancer

Exclusion

  • severe concomitant illness including severe psychiatric disorders
  • pregnancy
  • breast-feeding
  • incontinence
  • secondary malignancies
  • concurrent anti-tumor treatment